Compared to Estimates, CRH (CRH) Q2 Earnings: A Look at Key Metrics

CRH reported Q2 2025 revenue of $10.21 billion, a 5.7% year-over-year increase, which missed the Zacks consensus estimate by 1.19%. However, EPS reached $1.94, surpassing the consensus by 5.43% and up from $1.85 a year ago. Segment performance was mixed, with International Solutions revenue exceeding estimates while Americas Materials and Building Solutions slightly underperformed. Despite CRH shares outperforming the S&P 500 with a 3.5% gain over the past month, the stock carries a Zacks Rank #4 (Sell), indicating potential near-term underperformance.

Analysis

CRH Public Limited Company reported a mixed financial performance for its second quarter ending June 2025. While the company achieved year-over-year revenue growth of 5.7% to reach $10.21 billion, this figure fell short of the Zacks Consensus Estimate by 1.19%. In contrast, profitability exceeded expectations, with an EPS of $1.94, representing a 5.43% positive surprise over the consensus estimate of $1.84 and an increase from $1.85 in the prior-year period. A closer look at segmental revenue reveals a key source of the top-line miss: the Americas Materials Solutions division generated $4.51 billion, underperforming the analyst average estimate of $4.7 billion. The Americas Building Solutions segment also slightly missed its target. This weakness was partially offset by the International Solutions segment, which surpassed estimates with $3.54 billion in revenue. Despite the stock's recent outperformance, gaining 3.5% over the past month against the S&P 500 composite's 0.5% change, it currently holds a Zacks Rank #4 (Sell), signaling a professional analyst view of potential near-term market underperformance.

Key Decisions for Investors

• Investors should scrutinize the revenue miss in the Americas Materials Solutions segment as a potential indicator of softening demand or competitive pressure in a core market.
• The notable EPS beat of 5.43% suggests strong cost controls or margin management, which should be weighed against the top-line weakness to assess the quality and sustainability of earnings.
• Given the conflict between the stock's recent 3.5% outperformance and the newly issued Zacks Rank #4 (Sell), it is prudent to consider the risk of near-term price correction or underperformance as forecast by the rating.